Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.
Nasdaq4d
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
Novavax is also progressing well with its preclinical pipeline, which includes vaccines for RSV and H5N1 ... which provides a great opportunity to get in on the ground floor.
pharmaphorum2d
Novavax begins late-stage trial of COVID-19 vaccine in the UK
It’s one of several agreements with major vaccine makers as the UK hedges its bets over which of the shots will get okayed by regulators first. Novavax’s study is expected to recruit up to ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
The company has struggled to keep up with the pace of its rivals Moderna and Pfizer, which make messenger RNA-based vaccines ...